Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet ...

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of ...

Merck (MRK) announced the Japanese Ministry of Health, Labor and Welfare has approved new indications for KEYTRUDA or pembrolizumab, ...

Merck (NYSE: MRK) is a top pharmaceutical company ... One of the keys to replacing the lost revenue will be new drugs, including Winrevair, a treatment for pulmonary arterial hypertension.

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers. The FDA approves MRK's Keytruda for first-line ...

Merck Animal Health, a division of Merck & Co., Inc. (MRK), Tuesday announced the expansion of Nobivac NXT vaccine platform with the ...

The decision, which the U.S. Court of Appeals for the Third Circuit said was a close call, hinged on whether an informal ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

Shares of Merck & Co. Inc. MRK slipped 0.28% to $116.27 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0. ...

3 Big Pharma companies, 33 phase 3 trials: The race for supremacy in an ADC field In a second setback for Keytruda that Merck unveiled Thursday, the New Jersey pharma is discontinuing the phase 3 ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...